乳腺癌雌孕激素受体表达预测新辅助化疗敏感性的研究

Predicting the response of neoadjuvant chemotherapy by ER and/or PR status in patients with locally advanced breast cancer

目的探讨乳腺癌雌孕激素受体表达预测新辅助化疗有效性的可能性。方法应用免疫组织化学方法检测144例乳腺癌患者治疗前雌激素受体(ER)表达、孕激素受体(PR)表达,评估对新辅助化疗的敏感性。结果144例新辅助化疗乳腺癌患者中,ER阴性者新辅助化疗有效率为83.91%,ER阳性者为57.89%,差异有统计学意义(χ2=12.00,P<0.05);PR阴性者有效率为80.85%,PR阳性者为60.00%,差异有统计学意义(χ2=7.30,P<0.05);ER、PR双阴性组与ER、PR单阳或双阳性组有效率差异也有统计学意义(χ2=9.53,P<0.05)。结论ER或PR阴性患者对化疗更敏感,ER、PR可作为乳腺癌新辅助化疗有效性的预测指标。

Objective To investigate whether the expressions of ER and/or PR could predict the sensitivity of neoadjuvant chemotherapy in patients with breast cancers. Methods All 144 patients with breast cancers received neoadjuvant chemotherapy. The ER and PR expressions of tumors were determined preoperatively by immuno- histochemistry. The relationship of ER/PR status with response rate to neoadjuvant chemotherapy was then evaluated. Results Response rates of ER（-） and ER（＋） tumors to neoadjuvant chemotherapy were 83.91% and 57.89%; PR（-） and PR （＋） were 80.85% and 60.00% respectively. The significant differences were observed between ER （-） vs ER （＋）（X2=12.00, P〈0.05）and PR （-） vs PR （＋）（X27.30, P〈0.05）. The response rate in tumors with ER and PR absent tumors was significantly higher than that in ER and/or PR positive （x2=9.53, P〈0.05）. Conclusion ER and/or PR negative breast cancers were more sensitive to neoadjuvant chemotherapy, which indicated ER and PR might be predictive markers of neoadjuvant chemotherapy.